Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Prostate Cancer: early-phase trial registry
7 of 22 indexed Recurrent Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #756 of 28,707 conditions by registered trial count.
22 US clinical trials · 7 currently recruiting · #756 of 28,707 conditions by registered trial count
Recurrent Prostate Cancer: 22 US clinical trials tracked, 7 recruiting.
Recurrent Prostate Cancer is the subject of 22 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 7 of these trials.
Enrollment posture brief
Registry condition recurrent-prostate-cancer
OPEN 7 | RECR 32% | LATE 1 | EARLY 18 | RANK #756 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Childhood Obesity (32% recruiting · 44 trials)
Recurrent Prostate Cancer lists 7 open slots (32% of 22 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Prostate Cancer is recruiting below its size-band peers.
7 of 22 indexed trials (31.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Prostate Cancer research.
National Cancer Institute (NCI) accounts for 7 of 22 trials (31.8%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Prostate Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 49 among the 22 trials that report a genuine target (sentinel values excluded). 17 of those (77.3%) plan for fewer than 100 participants.
-
Recurrent Prostate Cancer research is mostly interventional.
21 interventional and 1 observational studies make up this index (95.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
22 total, page 1 of 1
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Mayo Clinic
NCT06378866
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
VA Office of Research and Development
NCT04787744
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
SpectraCure AB
NCT03067051
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
National Cancer Institute (NCI)
NCT06096870
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
H. Lee Moffitt Cancer Center and Research Institute
NCT03495427
Tumor Microenvironment Analysis of Prostate Cancer Metastasis
Columbia University
NCT05304858
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
University of Wisconsin, Madison
NCT07090148
Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer
University of Southern California
NCT01802346
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT01655836
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery
City of Hope Medical Center
NCT01923506
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Thomas Jefferson University
NCT02023463
Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer
Mark Stein
NCT05077098
Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
NCT00110214
Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
National Cancer Institute (NCI)
NCT00331344
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
University of Chicago
NCT02012296
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)
NCT00058253
Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer
National Cancer Institute (NCI)
NCT00103194
Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen
Ohio State University Comprehensive Cancer Center
NCT01682941
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
University of Chicago
NCT01599793
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
National Cancer Institute (NCI)
NCT00118092
Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
National Cancer Institute (NCI)
NCT01533246
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
Stanford University
NCT02184533
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 8 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Prostate Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Prostate Cancer page
22 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Recurrent Prostate Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Recurrent Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Prostate Cancer condition card totals 22 registered trials; most-linked intervention laboratory biomarker analysis; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.